#98 Is Diabetes a Coronary Heart Disease Equivalent?
CLINICAL QUESTION
Do patients with diabetes have the same risk of cardiovascular (CV) events as patients with existing coronary heart disease (CHD)?
BOTTOM LINE
Though diabetes does confer an increased risk of CV events, it is not automatically equivalent to having experienced a myocardial infarction (MI) (and thus does not always warrant aggressive pharmacotherapy). CV risk should be predicted, and therapy guided, by taking into account individual risk factors.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Meta-analysis1 of 13 observational studies (45,108 patients):
- Compared with patients with previous MI, diabetic patients have half the risk of CHD.
- Odds ratio 0.56 (95% confidence interval 0.53-0.60).
- After adjusting for some cardiac risk factors, socioeconomic status, and CV drugs:
- Diabetics had lower risk of MI or coronary death (hazard ratio 0.63 in men and 0.54 in women) than patients with prior MI.
- Limitations: No adjustment for most traditional risk factors (blood pressure, smoking status, etc.), which would have likely attenuated the association in diabetics further.
- Diabetes: 1.70 (1.66-1.74);
- Diabetes duration >10 years: 2.7 (2.6-2.8);
- Prior CHD: 2.76 (2.69-2.85);
- Both diabetes and prior CHD: 3.91 (3.78-4.05).
- North American guidelines4,5 no longer equate diabetes to existing CHD.
- Canadian cholesterol guidelines4 classify diabetics with ≥1 of the following as high-risk patients who may benefit from a statin:
- Age ≥40 years;
- Age ≥30 years and duration of diabetes >15 years; or
- Microvascular disease (nephropathy, neuropathy, retinopathy).
- The observational study6 that originally generated the concept of diabetes-CHD equivalence had multiple limitations, including selection bias and being very underpowered.
- Presence of diabetes approximately doubles the risk of CV events:3,7
- Associated risk further increased by longer duration of diabetes,3,8 increasing HbA1c,9 and traditional cardiac risk factors.10
- Most studies were completed in White individuals, and the applicability of this evidence to high-risk ethnic populations is unclear.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
